HC Wainwright & Co. Reiterates Neutral on Asensus Surgical, Maintains $0.35 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Neutral rating on Asensus Surgical (AMEX:ASXC) and maintained a price target of $0.35.

May 16, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated its Neutral rating on Asensus Surgical and maintained a price target of $0.35. This suggests that the analyst does not foresee significant short-term movement in the stock price.
The reiteration of a Neutral rating and maintenance of the price target at $0.35 indicates that the analyst does not expect significant short-term changes in the stock price. Investors might see this as a signal to hold rather than buy or sell.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100